At the U.S. "Pharma Spring Festival Gala," Chinese pharmaceutical companies have shifted from "optional consumption" to "essential consumption."

At the latest JPMorgan Global Healthcare Conference, discussions around mergers & acquisitions and external licensing (BD) have noticeably increased among many multinational pharmaceutical companies, with Chinese-origin innovative drug assets repeatedly included as a core topic.

According to Chasing Wind Trading Desk, JPMorgan analyzed the role change of Chinese innovative drugs in global allocation from the perspective of multinational pharmaceutical R&D and capital constraints, based on industry signals reflected by the conference in its latest report.

JPMorgan's conclusion is not “the comprehensive rise of Chinese pharma,” but rather a more specific and limited judgment: in certain technology platforms and therapeutic areas, Chinese innovative drugs have evolved from “optional allocation” to a category that multinational drug companies “must systematically evaluate during the asset screening stage.” However, this shift is highly dependent on clinical data, development pace, and globalization capabilities, and is not universal.

When M&A Becomes a Survival Tool, the "Accessibility" of External Assets Is Being Repriced

The report states that at this conference, multinational pharmaceutical companies repeatedly emphasized the importance of supplementing their pipelines through M&A and licensing, driven by a simple background: concentrated expiration of core patents, persistently low internal R&D returns, and intensified competition in key therapeutic areas have rendered sole reliance on in-house R&D uneconomical in terms of time and risk.

Under such constraints, the criteria for screening external assets have changed. Multinational pharmas now focus not only on technical concepts but on whether an asset can enter late-stage clinical or registration phases within a controllable timeframe.

It is within this screening logic that some Chinese-origin innovative drug assets have moved to a more prominent discussion spot—not due to “country advantage,” but because in certain areas they have achieved the maturity to connect with global development systems.

The Premise for Chinese Innovative Drugs Attracting Attention Is Clinical Progress, Not Cost Advantage

It should be clear that Chinese innovative drugs receiving attention does not mean their overall cost advantage is being “priced with a premium.” In fact, in the decisions of multinational pharmas, R&D cost is a secondary factor; the core is timing and certainty.

The report points out that in certain oncology, autoimmune, and metabolic indications, some Chinese pharma projects have already reached the forefront of global competition for the same targets. This leadership does not mainly stem from innovation in mechanisms, but more from clinical execution efficiency, patient recruitment speed, and progress in advancing indications.

When an asset has the opportunity to enter crucial clinical stages earlier, its commercial potential will naturally be evaluated in advance. This is the main reason Chinese assets are being systematically included in evaluations, not simply because “they’re cheap to value.”

External Licensing Is Becoming a Risk-Sharing Tool, Not a One-Way Value Transfer

Structurally, external licensing at this stage is more a risk management method than a passive cash-out. For Chinese innovative drug companies, the core functions of external licensing are:

On one hand, leveraging the clinical, registration, and commercialization systems of multinational pharmas to reduce uncertainty in global development for a single company; on the other hand, shifting asset valuation logic from a single regional market to broader global sales assumptions.

But this mechanism is not automatically established. Only when an asset possesses clear clinical positioning and scalability can external licensing truly amplify its long-term value; otherwise, a licensing transaction may be just a one-time financial arrangement.

The Current Change Is More Like an "Upgrade of Screening Mechanism" Than an Overall Industry Reappraisal

Based on information from the conference, a more accurate statement is not “Chinese pharma has entered the global core,” but that multinational pharmas are tightening and advancing their screening mechanisms for external assets. In this process, some Chinese innovative drug projects are entering the comparable and benchmarked range due to progress and data quality.

This means further intensification of differentiation within the Chinese pharma sector. Projects that can enter the global evaluation system may attract higher capital attention; those lacking clear clinical value may see their marginal appeal decline.

From an investment perspective, what’s truly worth tracking is whether specific projects possess the following characteristics:

Whether the clinical data is differentiated or clearly positioned, whether it can smoothly enter multi-regional clinical and registration pathways, and whether it has practical feasibility for integration by multinational pharmas.

Only under these premises can Chinese innovative drug projects transition from “comparison targets” to “transaction targets.”

Risks Still Mainly Concentrated in Clinical Results and Mismatched Development Pace

It must be emphasized that current trends do not weaken the inherent risks of the pharmaceutical industry. Clinical failures, shifts in competitive landscape, and regulatory uncertainty may still significantly impact the value judgment of individual assets. Additionally, if expectations for M&A and external licensing are excessively front-loaded, they may trigger temporary valuation fluctuations.

Therefore, evaluating the globalization potential of Chinese innovative drugs should always be based on verifiable data and pathways, not on narrative trends alone.

Overall, what the JPMorgan Global Healthcare Conference reflects is not emotional optimism toward Chinese pharma, but a more realistic, efficiency-oriented re-evaluation of external innovation sources by the global pharmaceutical industry under resource constraints. In this process, Chinese innovative drugs have entered the “must be evaluated” category in certain fields but this does not mean a universal revaluation of their value. The future key is not “whether it is Chinese,” but whether it can be continuously validated and integrated by the global system.

~~~~~~~~~~~~~~~~~~~~~~~~

The above excellent content comes from Chasing Wind Trading Desk.

For a more detailed interpretation, including real-time analysis and frontline research, please join [Chasing Wind Trading Desk • Annual Membership]

Risk Warning and DisclaimerThe market involves risks; investment requires caution. This article does not constitute personal investment advice, nor does it consider unique investment objectives, financial circumstances, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investment accordingly is at your own risk.